The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.
Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
Related items
:focal())
Securing Europe’s place in global life sciences
On Tuesday, 14 July, AmCham EU hosted Csaba Kontor, Policy Assistant, Cabinet of European Commissioner Olivér Várhelyi, for a discussion on strengthening Europe’s competitiveness in the life sciences sector. Moderated by Katerina Valkova (Bristol Myers Squibb), Chair, Healthcare Committee, AmCham EU, the exchange explored how policy decisions can support investment through research and innovation while ensuring patients in Europe can access health innovation. Participants also discussed the importance of resilient EU-US supply chains and regulatory cooperation, as well as the need to avoid divergence and provide the scale and predictability required to sustain Europe’s position as a leading destination for life sciences investment.
:focal())
A medical milestone, made in Denmark
Pfizer selected Denmark as the site of the largest vaccine registry study ever undertaken, demonstrating how Europe can attract world-leading life sciences investment when the right conditions are in place. Beginning in 2024, Pfizer partnered with researchers at the Center for Translational Cardiology and Pragmatic Randomized Trials at Herlev-Gentofte Hospital in Copenhagen to assess whether its respiratory syncytial virus vaccine could reduce hospitalisations in adults. Denmark’s innovation-friendly environment, national digital mailbox eBoks and world-class health registries enabled researchers to invite almost the entire adult population to take part, helping recruit more than 500,000 participants. Study materials were made available online, allowing participants to provide informed consent from home, while health registries supported comprehensive tracking and analysis. This milestone shows how strong public-private collaboration and a supportive policy framework can help Europe deliver clinical research at scale and improve health outcomes for citizens. Read the full story on Invested in Europe.
:focal())
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.